Acelrx enters into licensing agreement for dzuveo® in europe and in-licensing agreement for two products in the u.s.

Hayward, calif., july 14, 2021 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced agreements with laboratoire aguettant (aguettant) providing aguettant with a license to commercialize dzuveo in europe, and providing acelrx with two innovative pre-filled syringe product candidates for the u.s. under the dzuveo licensing agreement, aguettant will have the right to commercialize dzuveo in europe.
ACRX Ratings Summary
ACRX Quant Ranking